Prevention of recurrence and prolonged survival in primary central nervous system lymphoma (PCNSL) patients treated with adjuvant high-dose methylprednisolone

Medical Oncology

Volumn 16, Issue 3, 1999, Pages 211-215

  O'Neill, B P ^a   Habermann, T M ^a   Witzig, T E ^a   Rodriguez, M ^a  

^a MAYO CLINIC CANCER CENTER   (United States)

Author keywords

Adjuvant therapies; Brain tumors; Homing; Methylprednisolone; PCNSL

Indexed keywords

CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; METHOTREXATE; METHYLPREDNISOLONE; PREDNISONE; VINCRISTINE;

ADULT; AGED; ARTICLE; BLOOD BRAIN BARRIER; BRAIN LYMPHOMA; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL ARTICLE; DOSE RESPONSE; DRUG EFFICACY; HISTOPATHOLOGY; HUMAN; MALE; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL;

EID: 0032850639     PISSN: 07360118     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02906134     Document Type: Article

References (39)

1. Hochberg FH, Miller DC. Primary central nervous system lymphoma. J Neurosurg 1988; 68: 835-853.
2. O'Neill BP, Illig J. Primary central nervous system lymphoma. Mayo Clinic Proc 1989; 64: 1005-1020.
3. O'Neill BP, Dinapoli RP, Kurtin PJ, Habermann TM. Occult systemic non-Hodgkin's lymphoma (NHL) in patients initially diagnosed as primary central nervous system lymphoma (PCNSL): how much staging is enough? J Neuro-oncology 1995; 25: 67-71.
4. Jack CR, Jr, O'Neill BP, Banks PM, Reese DF. Primary central nervous system lymphoma: histologic subtypes and CT appearance. Radiology 1988; 167: 211-215.
5. O'Neill BP, Wang C-H, O'Fallon JR. Primary central nervous system non-Hodgkin's lymphoma: survival advantages with combined initial therapy? A final report of the North Central Cancer Treatment Group (NCCTG) Study 86-72-52. Int J Radiat Oncol Biol Phvs 1999; 43: 559-563.
6. Nelson DF et al. Non-Hodgkin's lymphoma of brain. Can high dose, large volume radiation therapy improve survival? Report on a prospective trial by the Radiation Therapy Oncology Group (RTOG): RTOG 8315. Int J Radiat Oncol Biol Phys 1992; 23: 9-17.
7. Bessell EM et al. Primary non-Hodgkin's lymphoma of the CNS treated with BVAM or CHOD/BVAM chemotherapy before radiotherapy. J Clin Oncol 1996; 14: 945-954.
8. Abrey LE, DeAngelis LM, Yahalom J. Long-term survival in primary CNS lymphoma. J Clin Oncol 1998; 16: 859-863.
9. Vaquera J, Martinez R, Rossi R, Lopez R. Primary cerebral lymphoma: the 'ghost tumor'. J Neurosurg 1984; 60: 174-176.
10. Ott RJ et al. Measurements of blood-brain barrier permeability in patients undergoing radiotherapy and chemotherapy for primary cerebral lymphoma. Eur J Cancer 1991; 27: 1356-1361.
11. Ueda FT et al. MR imaging of primary intracranial malignant lymphoma. Radiation Medicine 1995; 13: 51-57.
12. Molnar PP, O'Neill BP, Scheithauer BW, Groothuis DR. Endothelial cell death affects the blood-tumor barrier in primary CNS lymphoma. Ultrastructural observations and review of the literature. Neuro-Oncology (in press).
13. Hirano A, Ghatak NR, Becker NH, Zimmerman HM. A comparison of the fine structure of small blood vessels in intracranial and retroperitoneal malignant lymphomas. Acta Neuropathol 1974; 27: 93-104.
14. DeAngelis LM. Cerebral lymphoma presenting as a non-enhancing lesion on computed tomographic/magnetic resonance scan. Ann Neurol 1993; 33: 308-311.
15. Allegranza A, Mariani C, Giardini R, Brambilla MC, Boeri R. Primary malignant lymphomas of the central nervous system: a histological and immunohistological study of 12 cases. Histopathology 1984; 8: 781-791.
16. Gabbai AA, Hochberg FH, Linggood RM, Bashir R, Hotleman K. High-dose methotrexate for non-AIDS primary central nervous system lymphoma. J Neurosurg 1989; 70: 190-194.
17. Shibamoto Y et al. Improved survival rate in primary intracranial lymphoma treated by high-dose radiation and systemic vincristine, doxorubicin, cyclophosphamide, prednisolone chemotherapy. Cancer 1990; 65: 1907-1912.
18. Amadori S et al. Sequential combination of systemic high-dose ara-C and asparaginase for the treatment of central nervous system leukemia and lymphoma. J Clin Oncol 1984; 2: 98-101.
19. Loeffer JS et al. Primary lymphomas of the CNS: patterns of failure and factors that influence survival. J Clin Oncol 1985; 3: 490-494.
20. Posner JR. Intracranial metastases. Neurologic Complications of Cancer. FA Davis: Philadelphia, 1995, p 109.
21. Azzarelli B, Easterling K, Norton JA. Leukemic cell-endothelial cell interaction in leukemic cell dissemination. Lab Invest 1989; 60: 45-64.
22. Dunne JW, Harper CG, Pamphlett R. Intramedullary spinal cord metastases: A clinical and pathological study of nine cases. Quart J Med 1986; 61: 1003-1020.
23. Bashir R, Coakham H, Hochberg F. Expression of LFA-1/ICAM-1 in CNS lymphomas: possible mechanisms for lymphoma homing to the brain. J Neuro-oncol 1992; 12: 103-110.
24. Wilcox CE et al. Endothelial cell expression of the intracellular adhesion molecule-1 (ICAM-1) in the central nervous system of guinea pigs during acute and chronic relapsing experimental encephalomyelitis. J Neuroimmunol 1990; 30: 43-51.
25. Washington R et al. Expression of immunologically relevant endothelial cell activation antigens on isolated central nervous system microvessels from patients with multiple sclerosis. Ann Neurol 1994; 35: 89-87.
26. Frenette PS, Wagner DD. Adhesion molecules - Part I: cell adhesion molecules. N Engl J Med 1996; 334: 1526-1529.
27. Frenette PS, Wagner DD. Adhesion molecules - Part II: blood vessels and blood cells. N Engl J Med 1996; 335: 43-45.
28. Canella B, Cross AH, Raine CS. Adhesion-related molecules in the central nervous system: upregulation correlates with inflammatory cell influx during relapsing experimental autoimmune encephalomyelitis. Lab Invest 1991; 1: 23-31.
29. Oliveri RL et al. Randomized trial comparing two different high doses of methylprednisolone in MS: a clinical and MRI study. Neurology 1998; 50: 1833-1836.
30. Durelli L et al. High-dose intravenous methylprednisolone in the treatment of multiple sclerosis: clinical-immunologic correlations. Neurology 1986; 36: 238-243.
31. Trojano M et al. Soluble intercellular adhesion molecule-1 in serum and cerebrospinal fluid of clinically active relapsing-remitting multiple sclerosis: correlation with Gd-DPTA magnetic resonance imaging enhancement and cerebrospinal fluid findings. Neurology 1996; 46: 1535-1541.
32. Steffen BJ, Butcher EC, Engelhardt B. Evidence for involvement of ICAM-1 and VCAM-1 in lymphocyte interaction with endothelium in experimental autoimmune encephalomyelitis in the central nervous system in the SJL/J mouse. Am J Pathol 1994; 145: 189-201.
33. Gametchu B. Glucocorticoid receptor-like antigen in lymphoma cell membranes: correlation to cell lysis. Science 1987; 236: 456-461.
34. Ferreri AJM, Reni M, Villa E. Primary central nervous system lymphoma in immunocompetent patients. Cancer Treat Rev 1995; 21: 415-446.
35. Blay J-Y et al. Late neurological toxicity after the treatment of primary central nervous system lymphoma; multivariate analysis of 208 patients. J Clin Oncol 1998; 16: 864-871.
36. Schaller C, Kelly PJ. Primary central nervous system lymphoma (PCNSL): does age and histology at presentation affect outcome? Zent Neurochiurg 1996; 57: 56-62.
37. Miller DC et al. Pathology with clinical correlation of primary central nervous system non-Hodgkin's lymphoma. Cancer 1994; 74: 1383-1397.
38. Gill PS et al. Primary central nervous system lymphoma in homosexual men: clinical, immunologic and pathologic features. Am J Med 1985; 78: 742-748.
39. Corn BW, Marcus SM, Topham A, Hauck W, Curran WJ Jr. Will primary central nervous system lymphoma be the most frequent brain tumor diagnosed in the year 2000? Cancer 1997; 79: 2409-2413.